Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute is seeking R33 grant applications through the Innovative Molecular Analysis Technologies Program to support the development and validation of emerging technologies for cancer research and clinical care. This opportunity is specifically designed for projects that have already overcome major feasibility gaps and possess supportive preliminary data but require further optimization and rigorous technical validation to facilitate widespread adoption. Eligible projects must focus on enhancing capabilities in areas such as cancer biology, early detection, clinical diagnosis, treatment, and epidemiology, utilizing advanced platforms for molecular analysis, spatial profiling, imaging, or biospecimen processing. This forecast, issued by the National Institutes of Health under the Department of Health and Human Services, targets technologies with new or significantly improved technical capabilities to analyze cancer-related systems. Proposals must prioritize the development of the technology itself rather than the application of existing tools to new biological questions. Clinical trials are not allowed under this specific solicitation, and interested parties can contact the IMAT Program for further details.
General Info
Estimated contract value
Up to $300,000Place of Performance
Not specifiedSet-Aside
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies for cancer research or clinical care. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development, enhancements, optimizations, and rigorous technical validation to encourage adoption by the research community.
Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. Projects proposing application of existing technologies where the novelty resides in the clinical target or biological question being pursued are not appropriate for this solicitation.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health
Same awarding agency
Prepare for this forecast
Research this forecast and prepare for the solicitation
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
